[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331374-105":59,"doc-detail-331374-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-analysis-identifies-ykt6-as-a-potential-prognostic-and-diagnostic-biomarker-in-lung-adenocarcinoma","Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma","","YKT6 was evaluated as a candidate prognostic and diagnostic biomarker for lung adenocarcinoma (LUAD), where early detection and therapeutic outcomes remain limited. TCGA, HPA and UALCAN were used to assess YKT6 mRNA and protein patterns, and qRT-PCR, immunohistochemistry and tissue microarrays confirmed expression in human tissues. Functional assays showed that YKT6 knockdown suppresses proliferation and promotes apoptosis while reducing migration and invasion. Bioinformatics and PPI analyses linked YKT6-related genes to cell-cycle regulation and associated elevated expression with adverse clinicopathological features and poor survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-analysis-identifies-ykt6-as-a-potential-prognostic-and-diagnostic-biomarker-in-lung-adenocarcinoma/331374/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-analysis-identifies-ykt6-as-a-potential-prognostic-and-diagnostic-biomarker-in-lung-adenocarcinoma/331374.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is YKT6 and why was it studied in lung adenocarcinoma?","Question",{"text":112,"@type":113},"YKT6 is a SNARE family member. It was investigated because its clinical value and biological function in LUAD had not been established, while LUAD still lacks effective early diagnosis and has poor therapy outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were YKT6 expression levels measured and validated?",{"text":117,"@type":113},"YKT6 mRNA and protein levels were analyzed using TCGA, HPA and UALCAN, and were experimentally verified in tissues by qRT-PCR, immunohistochemistry and tissue microarrays (TMA).",{"name":119,"@type":110,"acceptedAnswer":120},"What did YKT6 knockdown do to LUAD cell behavior?",{"text":121,"@type":113},"Silencing YKT6 inhibited cell proliferation and promoted apoptosis. It also reduced the cells’ ability for migration and invasion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331374,1791018264,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Zhang et al. BMC Cancer (2024) 24:1235 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12975-3](https://doi.org/10.1186/s12885-024-12975-3)  \nRESEARCH Open Access  \nComprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma  \nLiming Zhang 1,2, Shaoqiang Wang3 and Lina Wang 1*  \nAbstract  \nBackground Lung cancer is the most common cause of cancer-related death worldwide. The most prevalent histological subtype of lung cancer is lung adenocarcinoma (LUAD), with incidence rising each year. Treating LUAD remains a significant issue due to a lack of early diagnosis and poor therapy outcomes. YKT6 is a member of the SNARE protein family, whose clinical value and biological function in LUAD has yet to be established.  \nMethods TCGA, HPA and UALCAN were used to analyze YKT6 mRNA and protein levels, the correlation between YKT6 expression and clinicopathological features and prognosis. YKT6 mRNA and protein expression were verified by qRT-PCR, immunohistochemistry (IHC) and tissue microarrays (TMA) . Additionally, lung cancer cell lines were chosen for YKT6 silencing to explore the effects on cell proliferation and migration. The cBioPortal was used to select YKT6-related genes. Protein-protein interaction (PPI) network was created based on STRING database and hub genes were screened, with their expression levels and prognosis values in LUAD analyzed accordingly. YKT6-related genes were enriched by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analyses.  \nResults In LUAD, YKT6 was distinctly highly expressed with relation to clinical features of staging, smoking, lymph node metastasis, andTP53 mutation. Elevated YKT6 expression was linked to adverse prognosis, serving as an independent unfavorable prognostic factor. Moreover, YKT6 presented high diagnostic value in LUAD patients (AUC = 0 . 856) . Experimental validation indicated that freshly collected LUAD tissues showed significantly high mRNA expression of YKT6 . IHC andTMA verified increasedYKT6 protein level in LUAD. Knockdown of YKT6 inhibited cell proliferation and promoted apoptosis, with mitigated capability of migration and invasion. The top ten hub genes screened by PPI network were highly expressed in LUAD, and significantly associated with poor prognosis. GO and KEGG analyses showed that YKT6-related genes were mainly involved in cell cycle.  \nConclusion Elevated YKT6 expression is related to poor prognosis of LUAD patients. YKT6 can serve as a novel biomarker for LUAD diagnosis and prognosis. Cell proliferation, migration and invasion was impaired with increased apoptosis upon YKT6 silencing in lung cancer cells. In summary, this study comprehensively uncovered that YKT6 could be identified as a potential prognostic and diagnostic biomarker in LUAD.  \nKeywords Lung adenocarcinoma (LUAD), YKT6, Prognosis, Biomarker, Bioinformatics analysis  \n*Correspondence:  \nLina Wang [wanglina_china@163.com](wanglina_china@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission d","cbCaiijIzeYiihEr","https://ap.wps.com/l/cbCaiijIzeYiihEr","pdf",10884676,17,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is YKT6 and why was it studied in lung adenocarcinoma?\",\"answer\":\"YKT6 is a SNARE family member. It was investigated because its clinical value and biological function in LUAD had not been established, while LUAD still lacks effective early diagnosis and has poor therapy outcomes.\"},{\"question\":\"How were YKT6 expression levels measured and validated?\",\"answer\":\"YKT6 mRNA and protein levels were analyzed using TCGA, HPA and UALCAN, and were experimentally verified in tissues by qRT-PCR, immunohistochemistry and tissue microarrays (TMA).\"},{\"question\":\"What did YKT6 knockdown do to LUAD cell behavior?\",\"answer\":\"Silencing YKT6 inhibited cell proliferation and promoted apoptosis. It also reduced the cells’ ability for migration and invasion.\"}]","Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma | PDF",1789993008,43]